Chronimed Begins Shipments of New Lasette and
DiaScreen Testing Products
MINNEAPOLIS, Nov. 4 /PRNewswire/ -- Chronimed Inc. (Nasdaq: CHMD - news), announced today that it has begun
shipping its new Lasette(TM) Laser Lancing Device as well as its new DiaScreen(R) Reagent Strips for Urinalysis to both
domestic and international customers.
As previously announced on August 4, Chronimed has exclusive worldwide rights to market and sell the patent-protected
Lasette laser technology products through its development and distribution agreement with Cell Robotics International, Inc.
(OTC: CRII - news). The Lasette laser finger perforator is a revolutionary device designed for drawing blood from fingertips in
a nearly painless manner for glucose testing. It utilizes a laser beam that penetrates the skin to obtain a capillary blood sample,
instead of traditional lancets that tear the skin. In addition to minimizing immediate and residual pain, the Lasette eliminates
accidental needle sticks, reduces cross contamination, eliminates sharps disposal, and can be used for testing glucose with any
standard blood glucose meter. The currently available institutional model of the Lasette is designed for use in clinical settings,
such as hospitals, clinics, blood banks and doctors' offices. The planned, second-generation model of the Lasette is a smaller
unit designed for convenient in-home use by consumers, and is pending regulatory approval.
Chronimed is now also launching the DiaScreen brand family of reagent strips for urinalysis, including the DiaScreen 10 with
leukocytes and specific gravity. With the introduction of these two tests, Chronimed now offers 14 different reagent strip
configurations. Urine test strips are used in physicians' offices, hospitals, and in the home to detect a variety of chronic health
conditions. Easy to use and non-invasive, a single DiaScreen test strip screens 10 different clinical markers in a patient's urine.
If positive, more definitive tests can be conducted to confirm a diagnosis.
Chronimed Inc. is a leading integrated healthcare company specializing in diagnostic products, specialty pharmacy services, and
disease management for people with chronic health conditions. The Company develops, manufactures, markets, and distributes
pharmaceuticals, medical diagnostic products, and provides specialized patient management services nationwide for people
with long-term chronic conditions such as HIV/AIDS, diabetes, organ transplants, and diseases treated with injectable
medications. Chronimed works directly with patients, providers, and payors to improve clinical and cost-of-care outcomes.
Chronimed's web site address is www.chronimed.com.
As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause
actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the
Company's ability to execute its service and product sales plans; changes in the status of managed care contracts; and the risks
described from time to time in the Company's SEC reports.
|
